Durable Remission for Four Pediatric Patients with High-Risk Relapsed Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin plus Gemcitabine but without Autologous Stem Cell Transplantation: A Report from the Children’s Oncology Group

While the majority of patients with complete responses to the brentuximab vedotin with gemcitabine regimen ultimately underwent high-dose chemotherapy and autologous stem cell transplantation (ASCT) consolidation, four subjects, reported herein, achieved durable complete remissions lasting more than four years after the study treatment but without ASCT consolidation.